🗞️ Why in News Following the expiry of Novo Nordisk’s semaglutide patent on March 20, 2026, multiple Indian pharmaceutical companies, Cipla, Sun Pharma, Dr Reddy’s, Biocon, Natco, Zydus, and Mankind Pharma, are preparing to launch generic versions at 50-70% lower prices, even as CDSCO intensifies surveillance against unauthorised GLP-1 sales.
The Editorial Argument
Business Standard argues that while India’s pharma industry is well-positioned to democratise access to semaglutide, one of the most transformative drugs of the decade, the country’s drug oversight system faces serious quality and counterfeiting risks that could undermine both patient safety and India’s global pharma reputation.
The Semaglutide Phenomenon
Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss) is a GLP-1 receptor agonist that mimics the incretin hormone, promoting insulin secretion and reducing appetite. It has become the fastest-growing drug category in pharmaceutical history:
| Parameter | Data |
|---|---|
| Global GLP-1 market (2025) | ~$40 billion |
| Novo Nordisk revenue from semaglutide (2025) | ~$30 billion |
| Weight loss efficacy | 15-20% body weight reduction in clinical trials |
| Patent expiry | March 20, 2026 |
| Indian generic price reduction expected | 50-70% |
Indian Companies Ready to Launch
| Company | Preparation Status |
|---|---|
| Cipla | ANDA filed, manufacturing ready |
| Sun Pharma | Clinical trials completed |
| Dr Reddy’s | Biosimilar route |
| Biocon | Biologics expertise leveraged |
| Natco | First-to-file advantage in select markets |
| Zydus | Injectable formulation ready |
| Mankind Pharma | Domestic market focus |
The Quality Challenge
The editorial highlights several risks:
- Counterfeiting: Semaglutide’s high demand and injectable format make it a prime target for counterfeit manufacturers
- Cold chain: GLP-1 agonists require 2-8°C storage; India’s cold chain infrastructure is uneven
- Off-label use: CDSCO has barred weight-loss drug advertisements, but online promotion continues
- Manufacturing complexity: Semaglutide is a peptide, more complex than small-molecule generics, requiring specialised production facilities
- Post-market surveillance: India’s pharmacovigilance system (PvPI) handles only a fraction of adverse drug reactions
CDSCO Regulatory Response
- Barred weight-loss drug advertisements to prevent off-label promotion
- Intensified surveillance and audits against unauthorised GLP-1 sales
- Government monitoring online pharmacies for prescription compliance
- WHO has flagged counterfeit semaglutide as a global concern
India’s Drug Regulatory Architecture
| Body | Role |
|---|---|
| CDSCO | Central regulator, new drug approvals, clinical trials, imports |
| DCGI | Drugs Controller General of India (heads CDSCO) |
| State Drug Controllers | Manufacturing and sales regulation |
| Indian Pharmacopoeia Commission | Drug quality standards |
| PvPI | Pharmacovigilance Programme of India (adverse event monitoring) |
| NLEM | National List of Essential Medicines |
The Bigger Picture: India’s Pharma Opportunity
The semaglutide moment represents a broader pattern: Indian companies excel at manufacturing complex generics at scale, driving down prices globally. The editorial argues this should be paired with regulatory modernisation to maintain credibility:
- India supplies 20% of global generic medicines
- Indian vaccines covered 60% of global immunisation
- But India’s WHO drug prequalification rejections remain a concern
UPSC Relevance
Prelims: GLP-1 receptor agonist, CDSCO, DCGI, Drugs and Cosmetics Act 1940, PvPI, NLEM, patent regime under TRIPS
Mains GS-3: India’s pharmaceutical industry; patent expiry and generic drug access; drug quality regulation
Mains GS-2: Drug regulatory governance; CDSCO capacity; public health policy
📌 Facts Corner: Knowledgepedia
Semaglutide:
- Drug class: GLP-1 receptor agonist
- Brand names: Ozempic (diabetes), Wegovy (weight loss)
- Original manufacturer: Novo Nordisk (Denmark)
- Patent expiry: March 20, 2026
- Weight loss: 15-20% body weight reduction
- Global GLP-1 market: ~$40 billion (2025)
- Indian generic price cut: 50-70%
Indian Companies Launching Generics:
- Cipla, Sun Pharma, Dr Reddy’s, Biocon, Natco, Zydus, Mankind Pharma
Drug Regulation in India:
- CDSCO: Central Drugs Standard Control Organisation
- DCGI: Drugs Controller General of India
- Drugs and Cosmetics Act, 1940
- PvPI: Pharmacovigilance Programme of India
- NLEM: National List of Essential Medicines (updated 2022)
Other Relevant Facts:
- India: “Pharmacy of the World”, 3rd largest by volume
- Generic share: 20% of global supply
- TRIPS Agreement: WTO patent regime (compulsory licensing under Section 84)
- Novartis v. Union of India (2013): Section 3(d) upheld, denying evergreening patents
- WHO prequalification: quality standard for global procurement
Sources: Business Standard, CDSCO
Interview Angle
"Semaglutide's patent expired on March 20, and Indian companies are launching generics at 50-70% lower prices. How should India balance affordable access with quality assurance for complex biologics?"
Cite this page: Semaglutide Goes Generic, Can India's Drug Oversight Keep Up with the Weight-Loss Revolution? — Ujiyari.com | Free UPSC & State PCS Editorial Analysis
